Iovance Biotherapeutics, INC Form 4 insider transactions

Frederick G. Vogt, Interim CEO & General Counsel at Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding on January 14, 2025.

Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding, resulting in a net change in his holdings.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding.

Director Ryan Maynard exercised stock options and sold shares of Iovance Biotherapeutics on November 12, 2024.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports acquisition of shares through RSU vesting and subsequent disposal to cover tax obligations.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Frederick Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports acquisition and disposal of common stock and restricted stock units.

Chief Medical Officer Friedrich Graf Finckenstein reports stock transactions related to vesting of restricted stock units.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Jean-Marc Bellemin, CFO of Iovance Biotherapeutics, filed a Form 4 detailing the vesting of restricted stock units and subsequent tax withholding.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, sold shares to cover tax obligations upon vesting of restricted stock units.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Athena Countouriotis, a director of Iovance Biotherapeutics, acquired 49,303 deferred restricted stock units (DRSUs) on June 11, 2024, under the company's 2018 Equity Incentive Plan.

Director Wendy L. Yarno reports acquisition of 49,303 deferred restricted stock units (DRSUs) of Iovance Biotherapeutics, Inc. on June 11, 2024.

Director Michael Weiser reports acquisition of deferred restricted stock units in Iovance Biotherapeutics.

Director Ryan Maynard acquired 49,303 deferred restricted stock units in Iovance Biotherapeutics, Inc. on June 11, 2024.

Director Iain D. Dukes reports acquisition of 98,607 deferred restricted stock units in Iovance Biotherapeutics.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.